Literature DB >> 29512775

SOX6 is downregulated in osteosarcoma and suppresses the migration, invasion and epithelial-mesenchymal transition via TWIST1 regulation.

Zheng Wang1, Junjie Li1, Kun Li2, Jianjun Xu1.   

Abstract

Transcription factor SOX6 (SOX6) has been reported to serve essential roles in numerous types of cancers. However, the expression and functions of SOX6 in osteosarcoma (OS) have not been analyzed. In the present study, the patterns of SOX6 expression in OS cell lines and tissues were investigated by reverse transcription‑quantitative polymerase chain reaction and western blotting. The results of the present study revealed that SOX6 was notably downregulated in OS tissues and cell lines. Subsequently, gain‑ and loss‑of‑function studies demonstrated that SOX6 inhibited OS cell migration and invasion. In addition, SOX6 may have suppressed epithelial‑mesenchymal transition via twist‑related protein 1 (TWIST1) modulation. Chromatin immunoprecipitation (ChIP), quantitative ChIP and dual luciferase activity assays were used to confirm the binding of SOX6 to the promoter region of TWIST1. Additionally, colony formation assays and Cell Counting Kit‑8 assays demonstrated that SOX6 suppressed cell proliferation. The findings of the present study indicated that SOX6 serves as a tumor suppressor in OS and may be a potential therapeutic target for OS.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29512775     DOI: 10.3892/mmr.2018.8681

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  5 in total

1.  Clinical implications and genetical insights of SOX6 expression in acute myeloid leukemia.

Authors:  Yan Li; Duanfeng Jiang; Qin Zhang; Enyi Liu; Haigang Shao
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-19       Impact factor: 4.322

2.  De Novo SOX6 Variants Cause a Neurodevelopmental Syndrome Associated with ADHD, Craniosynostosis, and Osteochondromas.

Authors:  Dara Tolchin; Jessica P Yeager; Priya Prasad; Naghmeh Dorrani; Alvaro Serrano Russi; Julian A Martinez-Agosto; Abdul Haseeb; Marco Angelozzi; G W E Santen; Claudia Ruivenkamp; Saadet Mercimek-Andrews; Christel Depienne; Alma Kuechler; Barbara Mikat; Hermann-Josef Ludecke; Frederic Bilan; Gwenael Le Guyader; Brigitte Gilbert-Dussardier; Boris Keren; Solveig Heide; Damien Haye; Hilde Van Esch; Liesbeth Keldermans; Damara Ortiz; Emily Lancaster; Ian D Krantz; Bryan L Krock; Kieran B Pechter; Alexandre Arkader; Livija Medne; Elizabeth T DeChene; Eduardo Calpena; Giada Melistaccio; Andrew O M Wilkie; Mohnish Suri; Nicola Foulds; Amber Begtrup; Lindsay B Henderson; Cara Forster; Patrick Reed; Marie T McDonald; Allyn McConkie-Rosell; Julien Thevenon; Pauline Le Tanno; Charles Coutton; Anne C H Tsai; Sarah Stewart; Ales Maver; Rudolf Gorazd; Olivier Pichon; Mathilde Nizon; Benjamin Cogné; Bertrand Isidor; Dominique Martin-Coignard; Radka Stoeva; Véronique Lefebvre; Cédric Le Caignec
Journal:  Am J Hum Genet       Date:  2020-05-21       Impact factor: 11.025

3.  Upregulation of miR-1269 Contributes to the Progression of Esophageal Squamous Cell Cancer Cells and Is Associated With Poor Prognosis.

Authors:  Xiuhui Bai; Qiang Wang; Xueqi Rui; Xiaohua Li; Xianming Wang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

4.  MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer.

Authors:  Hongxin Huang; Qin Han; Han Zheng; Mingchen Liu; Shu Shi; Ting Zhang; Xingwen Yang; Zhongqing Li; Qiang Xu; Hongyan Guo; Fengmin Lu; Jie Wang
Journal:  Cell Death Dis       Date:  2021-12-20       Impact factor: 8.469

5.  MiR-17-3p inhibits osteoblast differentiation by downregulating Sox6 expression.

Authors:  Nan Chen; Di Wu; Hua Li; Yi Liu; Hao Yang
Journal:  FEBS Open Bio       Date:  2020-10-25       Impact factor: 2.792

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.